兆科眼科-B(06622.HK):就於澳洲及新西蘭商業化BRIMOCHOL™ PF與AFT PHARMACEUTICALS訂立分銷協議
格隆匯1月13日丨兆科眼科-B(06622.HK)發佈公吿,公司與AFT Pharmaceuticals Limited(“AFT”,一間以新西蘭為基地的領先健康護理產品製造商及分銷商)就BRIMOCHOL™ PF(“該產品”)訂立分銷及供應協議。
BRIMOCHOL™ PF乃一種用於矯正因老花眼而喪失近距離視力的潛在療法。公司已就BRIMOCHOL™ PF與Tenpoint Therapeutics Ltd.(“Tenpoint”,通過Tenpoint Therapeutics Ltd.與Visus Therapeutics, Inc.合併成立)建立夥伴關係。Tenpoint為一間全球性臨牀階段生物技術公司,開發突破性的療法,以恢復老化眼睛的視力。
Tenpoint Therapeutics最近公佈了BRIO-II的積極頂線結果。BRIO-II為該公司的第二個第三期關鍵試驗。在該研究中,BRIMOCHOL™ PF成功達到美國及歐盟╱英國預定的視力主要研究終點,在8小時近距離視力方面具有重大統計顯著性改善,為2025年上半年在美國提交新藥申請鋪平道路。
根據協議條款,兆科眼科有權授予AFT於澳洲及新西蘭進口、分銷、推廣、營銷及銷售BRIMOCHOL™ PF的獨家權利。作為協議的一部分,AFT將代表公司取得相關的當地藥物註冊。公司將收取一筆不可退還及不可抵扣的預付款,並可按照若干成就獲得額外的里程碑付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.